Vitek 2 identification of three isolates (MSK4, MSK7 and MSK9) according to the CLSI/EUCAST guidelinea.
| Antimicrobial | MSK4 (MIC) | Interpretation | MSK7 (MIC) | Interpretation | MSK9 (MIC) | Interpretation | |
|---|---|---|---|---|---|---|---|
| β-lactam | Ampicillin | ≥32 | R | ≥32 | R | ≥32 | R |
| β-lactam+ β-lactamase inhibitor | Piperacillin/tazobactam | ≥128 | R | ≥128 | R | ≥128 | R |
| Amoxicillin/clavulanic acid | ≥32 | R | ≥32 | R | ≥32 | R | |
| Cephalosporin | Cefepime | ≥64 | R | 32 | R | 32 | R |
| Cefoperazone/sulbactam | ≥64 | R | ≥32 | *R | ≥64 | R | |
| Ceftriaxone | ≥64 | R | ≥64 | R | ≥64 | R | |
| Cefuroxime | ≥64 | R | ≥64 | R | ≥64 | R | |
| Cefuroxime axetil | ≥64 | R | ≥64 | R | ≥64 | R | |
| Carbapenem | Meropenem | ≥16 | R | 8 | R | 8 | R |
| Imipenem | 8 | R | ≤0.25* | *I | ≤0.25* | *I | |
| Ertapenem | ≥8 | R | 4 | R | ≥8 | R | |
| Aminoglycosides | Amikacin | ≥64 | R | ≥64 | R | ≥64 | R |
| Gentamicin | ≥16 | R | ≥16 | R | ≥16 | R | |
| Fluroquinolone | Ciprofloxacin | ≥4 | R | ≥4 | R | ≥8 | R |
| Nalidixic acid | ≥32 | R | ≥32 | R | ≥32 | R | |
| Nitrofuran | Nitrofurantoin | 128 | R | 64 | I | 128 | R |
| Polymyxin | Colistin | ≥16 | R | ≥8 | R | ≥16 | R |
| Folate pathway | Trimethoprim/sulfamethoxazole | ≤20 | S | ≥320 | R | ≥320 | R |
| Glycylcyclines | Tigecycline | 2 | S | ≤0.5 | S | 2 | S |
S: susceptible; I: intermediate; R: resistant; MIC: minimum inhibitory concentration.